Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of “Moderate Buy” from Analysts

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $46.43.

A number of research analysts have recently commented on the stock. Guggenheim upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Thursday, January 25th. Capital One Financial reiterated an “overweight” rating on shares of Outlook Therapeutics in a research report on Friday, February 16th. Ascendiant Capital Markets upped their target price on shares of Outlook Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. BTIG Research upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 target price for the company in a research report on Wednesday, March 27th. Finally, HC Wainwright upped their target price on shares of Outlook Therapeutics to $30.00 and gave the stock a “buy” rating in a research report on Monday, March 25th.

Outlook Therapeutics Price Performance

OTLK opened at $8.61 on Friday. The company has a fifty day moving average price of $8.62 and a 200-day moving average price of $8.38. The firm has a market capitalization of $112.02 million, a P/E ratio of -2.15 and a beta of 0.04. Outlook Therapeutics has a one year low of $4.00 and a one year high of $40.60.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.20. On average, analysts expect that Outlook Therapeutics will post -2.99 earnings per share for the current year.

Institutional Trading of Outlook Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA boosted its position in Outlook Therapeutics by 174.2% during the second quarter. BNP Paribas Arbitrage SA now owns 25,837 shares of the company’s stock valued at $26,000 after buying an additional 16,414 shares during the period. Tower Research Capital LLC TRC boosted its position in Outlook Therapeutics by 209.1% during the first quarter. Tower Research Capital LLC TRC now owns 23,546 shares of the company’s stock valued at $26,000 after buying an additional 15,928 shares during the period. Virtu Financial LLC bought a new position in shares of Outlook Therapeutics during the fourth quarter valued at about $27,000. Commonwealth Equity Services LLC raised its stake in shares of Outlook Therapeutics by 60.5% during the first quarter. Commonwealth Equity Services LLC now owns 26,522 shares of the company’s stock valued at $28,000 after acquiring an additional 10,000 shares during the last quarter. Finally, CI Private Wealth LLC bought a new position in shares of Outlook Therapeutics during the fourth quarter valued at about $31,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.